Form 8-K - Current report:
SEC Accession No. 0001171843-25-002981
Filing Date
2025-05-08
Accepted
2025-05-08 16:02:52
Documents
24
Period of Report
2025-05-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K f8k_050825.htm   iXBRL 8-K 30997
2 PRESS RELEASE exh_991.htm EX-99.1 51106
3 PRESS RELEASE exh_992.htm EX-99.2 16495
8 GRAPHIC table1.jpg GRAPHIC 65607
9 GRAPHIC fig1.jpg GRAPHIC 38919
10 GRAPHIC fig2.jpg GRAPHIC 33750
11 GRAPHIC fig3.jpg GRAPHIC 27188
12 GRAPHIC exh991_table1.jpg GRAPHIC 65607
13 GRAPHIC exh991_fig1.jpg GRAPHIC 38919
14 GRAPHIC exh991_fig2.jpg GRAPHIC 33750
15 GRAPHIC exh991_fig3.jpg GRAPHIC 27188
  Complete submission text file 0001171843-25-002981.txt   972185

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE gnw-20190101.xsd EX-101.SCH 3003
5 XBRL DEFINITION FILE gnw-20190101_def.xml EX-101.DEF 25598
6 XBRL LABEL FILE gnw-20190101_lab.xml EX-101.LAB 34011
7 XBRL PRESENTATION FILE gnw-20190101_pre.xml EX-101.PRE 22139
26 EXTRACTED XBRL INSTANCE DOCUMENT f8k_050825_htm.xml XML 3368
Mailing Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010
Business Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010 (650) 900-4520
Corvus Pharmaceuticals, Inc. (Filer) CIK: 0001626971 (see all company filings)

EIN.: 464670809 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37719 | Film No.: 25925850
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)